Literature DB >> 21036705

Orthotopic fluorescent peritoneal carcinomatosis model of esophageal cancer.

Stephanie J Gros1, Thorsten Dohrmann, Tamina Rawnaq, Nina Kurschat, Michael Bouvet, Johannes Wessels, Robert M Hoffmann, Jakob R Izbicki, Jussuf T Kaifi.   

Abstract

AIM: Orthotopic models utilizing orthotopic implantation have been used for developing cancer models of multiple tumor entities. The aim of this study was to evaluate the role of orthotopic injection in establishing a model of esophageal cancer using a human green fluorescent protein (GFP) cell line of human esophageal carcinoma.
MATERIALS AND METHODS: Nude mice were orthotopically injected in the abdominal esophagus with stably transfected GFP-PT1590 cells. Tumor progression was examined by fluorescence imaging.
RESULTS: Fifty percent of animals developed extensive peritoneal spread without a distinct primary tumor at the injection site. Continuous and metastatic spread to the liver, lungs, and lymph nodes was also observed. Fluorescence imaging enabled fast and specific visualization of tumor progression without the need for anesthesia. Intraperitoneal and metastatic tumor spread of GFP-PT1590 esophageal carcinoma demonstrated a highly aggressive but heterogeneous behaviour. Although injection of the esophageal carcinoma cell line GFP-PT1590 did not lead to primary esophageal tumor development at the site of injection, 50% of the mice developed extensive peritoneal spread, as well as lymph node and organ metastasis.
CONCLUSION: The orthotopic cell injection model resulted in peritoneal carcinomatosis of esophageal adenocarcinoma, which could be visualized in real time using fluorescence imaging.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21036705

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma.

Authors:  Shinichiro Watanabe; Kazuhiro Noma; Toshiaki Ohara; Hajime Kashima; Hiroaki Sato; Takuya Kato; Shinichi Urano; Ryoichi Katsube; Yuuri Hashimoto; Hiroshi Tazawa; Shunsuke Kagawa; Yasuhiro Shirakawa; Hisataka Kobayashi; Toshiyoshi Fujiwara
Journal:  Cancer Biol Ther       Date:  2019-06-11       Impact factor: 4.742

2.  Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.

Authors:  Theresa D Ahrens; Sylvia Timme; Jens Hoeppner; Jenny Ostendorp; Sina Hembach; Marie Follo; Ulrich T Hopt; Martin Werner; Hauke Busch; Melanie Boerries; Silke Lassmann
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

3.  New orthotopic implantation model of human esophageal squamous cell carcinoma in athymic nude mice.

Authors:  Shuai Song; Dong Chang; Yong Cui; Jian Hu; Min Gong; Kai Ma; Fang Ding; Zhi-Hua Liu; Tian-You Wang
Journal:  Thorac Cancer       Date:  2014-08-25       Impact factor: 3.500

4.  Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs.

Authors:  Isabella Monia Montagner; Anna Merlo; Gaia Zuccolotto; Davide Renier; Monica Campisi; Gianfranco Pasut; Paola Zanovello; Antonio Rosato
Journal:  PLoS One       Date:  2014-11-10       Impact factor: 3.240

5.  Improved xenograft efficiency of esophageal adenocarcinoma cell lines through in vivo selection.

Authors:  Elodie Melsens; Elly De Vlieghere; Benedicte Descamps; Christian Vanhove; Olivier De Wever; Wim Ceelen; Piet Pattyn
Journal:  Oncol Rep       Date:  2017-05-15       Impact factor: 3.906

6.  Novel metastatic models of esophageal adenocarcinoma derived from FLO-1 cells highlight the importance of E-cadherin in cancer metastasis.

Authors:  David S Liu; Sanne J M Hoefnagel; Oliver M Fisher; Kausilia K Krishnadath; Karen G Montgomery; Rita A Busuttil; Andrew J Colebatch; Matthew Read; Cuong P Duong; Wayne A Phillips; Nicholas J Clemons
Journal:  Oncotarget       Date:  2016-12-13

7.  Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer.

Authors:  Stephanie J Gros; Nina Kurschat; Astrid Drenckhan; Thorsten Dohrmann; Evelyn Forberich; Katharina Effenberger; Uta Reichelt; Robert M Hoffman; Klaus Pantel; Jussuf T Kaifi; Jakob R Izbicki
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.